The preamble also describes the seven alternatives considered by FDA in promulgating this rule and why it believes that the alternative selected (the mammalian-to-ruminant prohibition--with exceptions) is the most cost-effective regulatory alternative that meets the objective of the agency.
The preamble describes less than 8 alternative considered by the FDA.